Johnson & Johnson’s Stock Price Dips to $248.61, Notching a Significant 5.73% Decline

Johnson & Johnson (JNJ)

248.61 USD -15.12 (-5.73%) Volume: 16.61M

Johnson & Johnson’s stock price stands at 248.61 USD, witnessing a drop of -5.73% this trading session with a trading volume of 16.61M, however, its year-to-date performance shows a promising surge of +20.13%, reflecting its robust market presence.

Latest developments on Johnson & Johnson

Despite strong earnings, Johnson & Johnson‘s stock fell as investors focused on the underperformance of its medtech unit. The company’s new pharma chief is optimistic about the launch momentum of Icotyde for psoriasis and expects similar success across other indications. However, weak medical device sales led to a decline in shares. J&J set a mid-2027 target for an orthopedics spinoff as Q3 medtech sales missed estimates. Although the company raised profit guidance in its Q3 2026 earnings report, the stock price still fell. The medtech business continued to slow in Q3, impacting overall performance despite positive developments in other areas.

A look at Johnson & Johnson Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Johnson & Johnson, a company known for manufacturing health care products, has received a mixed outlook based on the Smartkarma Smart Scores. While it scores well in areas such as Dividend and Momentum, indicating stability and positive market performance, its Value and Growth scores are more moderate. This suggests that while the company may provide a reliable dividend and show strong market momentum, there may be some concerns about its valuation and potential for future growth.

Overall, Johnson & Johnson‘s resilience score is also moderate, indicating that the company may be able to withstand economic challenges and market fluctuations. With a diverse range of products in the consumer, pharmaceutical, and medical devices markets, Johnson & Johnson continues to be a key player in the global health care industry, providing essential products and services to customers worldwide.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma